Spleen cells from immunised BALB/c were fused with cells of the NSO mouse myeloma cell line
Store at +4oC or at -20oC if preferred.
This product should be stored undiluted.
Storage in frost-free freezers is not recommended. This product is photosensitive and should be protected from light.
Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
18 months from date of despatch.
For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.
Please view the datasheet pdf for suggested dilutions.
Use 10ul of the suggested working dilution to label 106 lymphocytes in 100ul
1. Willett, B.J. et al. (1994) The generation of monoclonal antibodies recognising novel epitopes by immunisation with solid matrix antigen-antibody complexes reveals a polymorphic determinant on feline CD4.J. Immunol. Methods. 176: 213-220.
3. Campbell, D.J. et al. (2004) Insulin-like growth factor-I (IGF-I) and its association with lymphocyte homeostasis in the ageing cat.Mech Ageing Dev. 125: 497-505.
4. Veir, J.K. et al. (2007) Effect of supplementation with Enterococcus faecium (SF68) on immune functions incats.Vet Ther. 8: 229-38.
5. Freer, G. et al. (2008) Immunotherapy with internally inactivated virus loaded dendritic cells boosts cellular immunity but does not affect feline immunodeficiency virus infection course.Retrovirology. 5: 33.
6. Pistello, M. et al. (2010) Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.J Virol. 84: 3845-56.
7. Willett, B.J. et al. (2007) Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand.J Virol. 81: 9665-79.
10. Flynn, J.N. et al. (2002) Longitudinal analysis of feline leukemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection.J Virol. 76: 2306-15.
11. Hosie, M.J. et al. (2000) Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.J Virol. 74: 9403-11.
12. Hosie, M.J. et al. (2002) Evolution of replication efficiency following infection with a molecularly cloned feline immunodeficiency virus of low virulence.J Virol. 76: 6062-72.